Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 215

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults

Open access
Jessup, Mariell, Abraham, William T., Casey, Donald E., Feldman, Arthur M., Francis, Gary S., Ganiats, Theodore G., Konstam, Marvin A., Mancini, Donna M., Rahko, Peter S., Silver, Marc A., Stevenson, Lynne Warner, Yancy, Clyde W. · 2009 · Journal of the American College of Cardiology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2008.11.009

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 311

  1. Hunt, 2005, J Am Coll Cardiol, 46, e1, 10.1016/j.jacc.2005.08.022 · DOI · Paper page
  2. Jessup, 2008, 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of chronic heart failure in adults with the 2008 focused update incorporated, J Am Coll Cardiol, 53, e1
  3. Alderman, 1983, Results of coronary artery surgery in patients with poor left ventricular function (CASS), Circulation, 68, 785, 10.1161/01.CIR.68.4.785 · DOI · Paper page
  4. Eagle, 2004, Circulation, 110, e340
  5. Fox, 2001, Coronary artery disease as the cause of incident heart failure in the population, Eur Heart J, 22, 228, 10.1053/euhj.2000.2289 · DOI · Paper page
  6. Arques, 2004, Prevalence of angiographic coronary artery disease in patients hospitalized for acute diastolic heart failure without clinical and electrocardiographic evidence of myocardial ischemia on admission, Am J Cardiol, 94, 133, 10.1016/j.amjcard.2004.03.046 · doi:10.1016/j.amjcard.2004.03.046
  7. Kurtz, 2006, Use of ejection fraction tests and coronary angiography in patients with heart failure, Mayo Clin Proc, 81, 906, 10.4065/81.7.906 · DOI
  8. Elhendy, 2004, Incidence and predictors of heart failure during long-term follow-up after stress Tc-99m sestamibi tomography in patients with suspected coronary artery disease, J Nucl Cardiol, 11, 527, 10.1016/j.nuclcard.2004.04.011 · DOI
  9. Chomsky, 1996, Hemodynamic exercise testing, Circulation, 94, 3176, 10.1161/01.CIR.94.12.3176 · DOI · Paper page
  10. Gullestad, 1998, Serial exercise testing and prognosis in selected patients considered for cardiac transplantation, Am Heart J, 135, 221, 10.1016/S0002-8703(98)70085-7 · DOI
  11. Mehra, 2006, Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006, J Heart Lung Transplant, 25, 1024, 10.1016/j.healun.2006.06.008 · DOI · Paper page
  12. de Lemos, 2003, B-type natriuretic peptide in cardiovascular disease, Lancet, 362, 316, 10.1016/S0140-6736(03)13976-1 · DOI · Paper page
  13. Siebert, 2006, Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department, Am J Cardiol, 98, 800, 10.1016/j.amjcard.2006.06.005 · DOI
  14. Gackowski, 2004, Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure, Eur Heart J, 25, 1788, 10.1016/j.ehj.2004.07.038 · DOI
  15. Bayes-Genis, 2004, N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction, Eur J Heart Fail, 6, 301, 10.1016/j.ejheart.2003.12.013 · DOI · Paper page
  16. Dao, 2001, Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting, J Am Coll Cardiol, 37, 379, 10.1016/S0735-1097(00)01156-6 · DOI · Paper page
  17. Worster, 2008, Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review, Clin Biochem, 41, 250, 10.1016/j.clinbiochem.2007.08.008 · DOI
  18. O'Donoghue, 2007, Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study), Am J Cardiol, 100, 1336, 10.1016/j.amjcard.2007.06.020 · DOI
  19. Silvers, 2007, Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes, Ann Emerg Med, 49, 627, 10.1016/j.annemergmed.2006.10.024 · DOI
  20. Gibbons, 2002, ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines), J Am Coll Cardiol, 40, 1531, 10.1016/S0735-1097(02)02164-2 · DOI · Paper page
  21. Vitarelli, 2003, The role of echocardiography in the diagnosis and management of heart failure, Heart Fail Rev, 8, 181, 10.1023/A:1023001104207 · DOI
  22. Ritchie, 1995, Guidelines for clinical use of cardiac radionuclide imaging, J Am Coll Cardiol, 25, 521, 10.1016/0735-1097(95)90027-6 · DOI · Paper page
  23. Bello, 2003, Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy, Circulation, 108, 1945, 10.1161/01.CIR.0000095029.57483.60 · DOI · Paper page
  24. Troughton, 2000, Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations, Lancet, 355, 1126, 10.1016/S0140-6736(00)02060-2 · DOI · Paper page
  25. Weinfeld, 1999, Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure, Am Heart J, 138, 285, 10.1016/S0002-8703(99)70113-4 · DOI · Paper page
  26. Maisel, 2001, B-type natriuretic peptide levels: a potential novel “white count” for congestive heart failure, J Card Fail, 7, 183, 10.1054/jcaf.2001.24609 · DOI
  27. Mueller, 2004, Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea, N Engl J Med, 350, 647, 10.1056/NEJMoa031681 · DOI · Paper page
  28. Mehra, 2004, Obesity and suppressed B-type natriuretic peptide levels in heart failure, J Am Coll Cardiol, 43, 1590, 10.1016/j.jacc.2003.10.066 · DOI · Paper page
  29. Wright, 2003, Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial, J Am Coll Cardiol, 42, 1793, 10.1016/j.jacc.2003.05.011 · DOI · Paper page
  30. Tang, 2003, Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure, Circulation, 108, 2964, 10.1161/01.CIR.0000106903.98196.B6 · DOI · Paper page
  31. Mahdyoon, 1989, Radiographic pulmonary congestion in end-stage congestive heart failure, Am J Cardiol, 63, 625, 10.1016/0002-9149(89)90912-0 · DOI
  32. Aaronson, 1997, Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation, Circulation, 95, 2660, 10.1161/01.CIR.95.12.2660 · DOI · Paper page
  33. Levy, 2006, The Seattle Heart Failure Model: prediction of survival in heart failure, Circulation, 113, 1424, 10.1161/CIRCULATIONAHA.105.584102 · DOI · Paper page
  34. Butler, 2004, Selection of patients for heart transplantation in the current era of heart failure therapy, J Am Coll Cardiol, 43, 787, 10.1016/j.jacc.2003.08.058 · DOI
  35. Zipes, 2006, J Am Coll Cardiol, 48, e247, 10.1016/j.jacc.2006.07.010 · DOI · Paper page
  36. 1983, A placebo-controlled trial of captopril in refractory chronic congestive heart failure, J Am Coll Cardiol, 2, 755, 10.1016/S0735-1097(83)80316-7 · DOI · Paper page
  37. Garg, 1995, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure, JAMA, 273, 1450, 10.1001/jama.1995.03520420066040 · DOI · Paper page
  38. Sharpe, 1984, Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study, Circulation, 70, 271, 10.1161/01.CIR.70.2.271 · DOI · Paper page
  39. Chalmers, 1987, Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study, J Cardiovasc Pharmacol, 9, S89, 10.1097/00005344-198700003-00021 · DOI
  40. Cleland, 1984, Captopril in heart failure, Br Heart J, 52, 530, 10.1136/hrt.52.5.530 · DOI · Paper page
  41. Cleland, 1985, Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state, Br Heart J, 54, 305, 10.1136/hrt.54.3.305 · DOI · Paper page
  42. Cowley, 1982, Captopril therapy for heart failure, Lancet, 2, 730, 10.1016/S0140-6736(82)90920-5 · DOI
  43. Bayliss, 1985, Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin, Br Med J (Clin Res Ed), 290, 1861, 10.1136/bmj.290.6485.1861 · DOI
  44. Drexler, 1989, Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure, Circulation, 79, 491, 10.1161/01.CIR.79.3.491 · DOI · Paper page
  45. Erhardt, 1995, Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure, Eur Heart J, 16, 1892, 10.1093/oxfordjournals.eurheartj.a060844 · DOI
  46. 1987, Effects of enalapril on mortality in severe congestive heart failure, N Engl J Med, 316, 1429, 10.1056/NEJM198706043162301 · DOI · Paper page
  47. 1999, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9 · DOI · Paper page
  48. 2001, A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure, N Engl J Med, 344, 1659, 10.1056/NEJM200105313442202 · DOI · Paper page
  49. Poole-Wilson, 2003, Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial, Lancet, 362, 7, 10.1016/S0140-6736(03)13800-7 · DOI · Paper page
  50. 1999, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 · DOI · Paper page
  51. Lechat, 1998, Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials, Circulation, 98, 1184, 10.1161/01.CIR.98.12.1184 · DOI · Paper page
  52. Packer, 1996, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, N Engl J Med, 334, 1349, 10.1056/NEJM199605233342101 · DOI · Paper page
  53. Dargie, 2001, Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial, Lancet, 357, 1385, 10.1016/S0140-6736(00)04560-8 · DOI · Paper page
  54. Cleland, 2003, Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial, Lancet, 362, 14, 10.1016/S0140-6736(03)13801-9 · DOI · Paper page
  55. Fisher, 1994, Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial, J Am Coll Cardiol, 23, 943, 10.1016/0735-1097(94)90641-6 · DOI · Paper page
  56. Metra, 1994, Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy, J Am Coll Cardiol, 24, 1678, 10.1016/0735-1097(94)90174-0 · DOI · Paper page
  57. Olsen, 1995, Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study, J Am Coll Cardiol, 25, 1225, 10.1016/0735-1097(95)00012-S · DOI · Paper page
  58. Krum, 1995, Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure, Circulation, 92, 1499, 10.1161/01.CIR.92.6.1499 · DOI · Paper page
  59. Waagstein, 1993, Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy, Lancet, 342, 1441, 10.1016/0140-6736(93)92930-R · DOI · Paper page
  60. 1994, Circulation, The Cardiac Insufficiency Bisoprolol Study (CIBIS), 90, 1765
  61. Packer, 1996, Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure, Circulation, 94, 2793, 10.1161/01.CIR.94.11.2793 · DOI · Paper page
  62. Colucci, 1996, Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure, Circulation, 94, 2800, 10.1161/01.CIR.94.11.2800 · DOI · Paper page
  63. 1997, Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease, Lancet, 349, 375, 10.1016/S0140-6736(97)80008-6 · DOI · Paper page
  64. Gottlieb, 1993, Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure, Circulation, 88, 1602, 10.1161/01.CIR.88.4.1602 · DOI · Paper page
  65. Crozier, 1995, Losartan in heart failure, Circulation, 91, 691, 10.1161/01.CIR.91.3.691 · DOI · Paper page
  66. Riegger, 1999, Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil, Circulation, 100, 2224, 10.1161/01.CIR.100.22.2224 · DOI · Paper page
  67. Sharma, 2000, Meta-analysis of observed mortality data from all-controlled, double- blind, multiple-dose studies of losartan in heart failure, Am J Cardiol, 85, 187, 10.1016/S0002-9149(99)00646-3 · DOI
  68. McKelvie, 1999, Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study, Circulation, 100, 1056, 10.1161/01.CIR.100.10.1056 · DOI · Paper page
  69. Mazayev, 1998, Valsartan in heart failure patients previously untreated with an ACE inhibitor, Int J Cardiol, 65, 239, 10.1016/S0167-5273(98)00149-1 · DOI
  70. Wong, 2002, Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study, J Am Coll Cardiol, 40, 970, 10.1016/S0735-1097(02)02063-6 · DOI · Paper page
  71. Heerdink, 1998, NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics, Arch Intern Med, 158, 1108, 10.1001/archinte.158.10.1108 · DOI · Paper page
  72. Herchuelz, 1989, Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance, J Pharmacol Exp Ther, 248, 1175, 10.1016/S0022-3565(25)24138-6 · DOI
  73. Gottlieb, 1992, Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, Am J Cardiol, 70, 890, 10.1016/0002-9149(92)90733-F · DOI
  74. Bank, 1991, Local forearm vasodilation with intra-arterial administration of enalaprilat in humans, Clin Pharmacol Ther, 50, 314, 10.1038/clpt.1991.142 · DOI
  75. 1989, Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction, N Engl J Med, 321, 406, 10.1056/NEJM198908103210629 · DOI · Paper page
  76. 1992, Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction, N Engl J Med, 327, 227, 10.1056/NEJM199207233270403 · DOI · Paper page
  77. Pratt, 1989, The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio, Am Heart J, 118, 433, 10.1016/0002-8703(89)90254-8 · DOI
  78. Nilsson, 2008, Effects of group-based high-intensity aerobic interval training in patients with chronic heart failure, Am J Cardiol, 102, 1361, 10.1016/j.amjcard.2008.07.016 · DOI
  79. Mueller, 2007, Exercise capacity, physical activity patterns and outcomes six years after cardiac rehabilitation in patients with heart failure, Clin Rehabil, 21, 923, 10.1177/0269215507079097 · DOI
  80. Dracup, 2007, Effects of a home-based exercise program on clinical outcomes in heart failure, Am Heart J, 154, 877, 10.1016/j.ahj.2007.07.019 · DOI
  81. Jónsdóttir, 2006, The effect of physical training in chronic heart failure, Eur J Heart Fail, 8, 97, 10.1016/j.ejheart.2005.05.002 · DOI · Paper page
  82. Bokhari, 2004, Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS), Circulation, 110, 112, 10.1161/01.CIR.0000134957.51747.6E · DOI · Paper page
  83. Mark, 2006, Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), Circulation, 114, 135, 10.1161/CIRCULATIONAHA.105.581884 · DOI · Paper page
  84. Hebert, 2006, Expansion of heart failure device therapy into a rural indigent population in Louisiana: potential economic and health policy implications, J Card Fail, 12, 689, 10.1016/j.cardfail.2006.08.214 · doi:10.1016/j.cardfail.2006.08.214
  85. Knight, 1999, Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator, J Am Coll Cardiol, 33, 1964, 10.1016/S0735-1097(99)00148-5 · DOI · Paper page
  86. Klein, 2000, The MUSTT study: evaluating testing and treatment, J Interv Card Electrophysiol, 4, 45, 10.1023/A:1009862028599 · DOI
  87. Moss, 2002, Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction, N Engl J Med, 346, 877, 10.1056/NEJMoa013474 · DOI · Paper page
  88. Hohnloser, 2000, The defibrillator in acute myocardial infarction trial (DINAMIT): study protocol, Am Heart J, 140, 735, 10.1067/mhj.2000.110088 · DOI
  89. Beshai, 2007, Cardiac-resynchronization therapy in heart failure with narrow QRS complexes, N Engl J Med, 357, 2461, 10.1056/NEJMoa0706695 · DOI · Paper page
  90. Cleland, 2005, The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med, 352, 1539, 10.1056/NEJMoa050496 · DOI · Paper page
  91. Higgins, 2003, Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias, J Am Coll Cardiol, 42, 1454, 10.1016/S0735-1097(03)01042-8 · DOI · Paper page
  92. Xiao, 1996, Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy, Int J Cardiol, 53, 163, 10.1016/0167-5273(95)02502-2 · DOI · Paper page
  93. Shamim, 1999, Intraventricular conduction delay: a prognostic marker in chronic heart failure, Int J Cardiol, 70, 171, 10.1016/S0167-5273(99)00077-7 · DOI · Paper page
  94. Unverferth, 1984, Factors influencing the one-year mortality of dilated cardiomyopathy, Am J Cardiol, 54, 147, 10.1016/0002-9149(84)90320-5 · DOI · Paper page
  95. Blanc, 1997, Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study, Circulation, 96, 3273, 10.1161/01.CIR.96.10.3273 · DOI · Paper page
  96. Kass, 1999, Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay, Circulation, 99, 1567, 10.1161/01.CIR.99.12.1567 · DOI · Paper page
  97. Toussaint, 2000, Biventricular pacing in severe heart failure patients reverses electromechanical dyssynchronization from apex to base, Pacing Clin Electrophysiol, 23, 1731, 10.1111/j.1540-8159.2000.tb07006.x · DOI
  98. Nelson, 2000, Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block, Circulation, 102, 3053, 10.1161/01.CIR.102.25.3053 · DOI · Paper page
  99. Young, 2003, Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial, JAMA, 289, 2685, 10.1001/jama.289.20.2685 · DOI
  100. McAlister, 2004, Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials, J Am Coll Cardiol, 44, 810
  101. Leclercq, 2002, Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation, Eur Heart J, 23, 1780, 10.1053/euhj.2002.3232 · DOI · Paper page
  102. Leon, 2002, Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing, J Am Coll Cardiol, 39, 1258, 10.1016/S0735-1097(02)01779-5 · DOI · Paper page
  103. Juurlink, 2003, Drug-drug interactions among elderly patients hospitalized for drug toxicity, JAMA, 289, 1652, 10.1001/jama.289.13.1652 · DOI · Paper page
  104. Juurlink, 2004, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study, N Engl J Med, 351, 543, 10.1056/NEJMoa040135 · DOI · Paper page
  105. Svensson, 2004, How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?, J Card Fail, 10, 297, 10.1016/j.cardfail.2003.10.012 · DOI
  106. Carson, 1999, Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials, J Card Fail, 5, 178, 10.1016/S1071-9164(99)90001-5 · DOI · Paper page
  107. Stevenson, 2007, Management of atrial fibrillation in patients with heart failure, Heart Rhythm, 4, S28, 10.1016/j.hrthm.2006.12.003 · DOI
  108. Heist, 2006, Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment, Prog Cardiovasc Dis, 48, 256, 10.1016/j.pcad.2005.09.001 · DOI
  109. Van Gelder, 2002, A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation, N Engl J Med, 347, 1834, 10.1056/NEJMoa021375 · DOI · Paper page
  110. 1988, Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure, JAMA, 259, 539, 10.1001/jama.1988.03720040031022 · DOI · Paper page
  111. Dobbs, 1977, Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients, Br Med J, 1, 749, 10.1136/bmj.1.6063.749 · DOI · Paper page
  112. Lee, 1982, Heart failure in outpatients: a randomized trial of digoxin versus placebo, N Engl J Med, 306, 699, 10.1056/NEJM198203253061202 · DOI · Paper page
  113. Guyatt, 1988, A controlled trial of digoxin in congestive heart failure, Am J Cardiol, 61, 371, 10.1016/0002-9149(88)90947-2 · DOI · Paper page
  114. DiBianco, 1989, A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure, N Engl J Med, 320, 677, 10.1056/NEJM198903163201101 · DOI · Paper page
  115. Uretsky, 1993, Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial, J Am Coll Cardiol, 22, 955, 10.1016/0735-1097(93)90403-N · DOI · Paper page
  116. Packer, 1993, Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors, N Engl J Med, 329, 1, 10.1056/NEJM199307013290101 · DOI · Paper page
  117. Cohn, 1993, The Vasodilator-Heart Failure Trials (V-HeFT), Circulation, 87, VI1
  118. Cazeau, 2001, Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay, N Engl J Med, 344, 873, 10.1056/NEJM200103223441202 · DOI · Paper page
  119. Loeb, 1993, Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure, Circulation, 87, VI78
  120. 1988, The effect of diltiazem on mortality and reinfarction after myocardial infarction, N Engl J Med, 319, 385, 10.1056/NEJM198808183190701 · DOI · Paper page
  121. Reed, 2004, Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT), Am Heart J, 148, 122, 10.1016/j.ahj.2003.12.040 · DOI
  122. Setaro, 1990, Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance, Am J Cardiol, 66, 981, 10.1016/0002-9149(90)90937-V · DOI · Paper page
  123. Packer, 1996, Effect of amlodipine on morbidity and mortality in severe chronic heart failure, N Engl J Med, 335, 1107, 10.1056/NEJM199610103351504 · DOI · Paper page
  124. McKelvie, 1995, Effects of exercise training in patients with congestive heart failure: a critical review, J Am Coll Cardiol, 25, 789, 10.1016/0735-1097(94)00428-S · DOI · Paper page
  125. Chati, 1996, Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure, Am Heart J, 131, 560, 10.1016/S0002-8703(96)90537-2 · DOI
  126. Sinoway, 1988, Effect of conditioning and deconditioning stimuli on metabolically determined blood flow in humans and implications for congestive heart failure, Am J Cardiol, 62, 45E, 10.1016/S0002-9149(88)80010-9 · DOI
  127. Mancini, 1992, Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure, Circulation, 85, 1364, 10.1161/01.CIR.85.4.1364 · DOI · Paper page
  128. Packer, 1991, Hemodynamic consequences of antiarrhythmic drug therapy in patients with chronic heart failure, J Cardiovasc Electrophysiol, 2, S240
  129. Torp-Pedersen, 1999, Dofetilide in patients with congestive heart failure and left ventricular dysfunction, N Engl J Med, 341, 857, 10.1056/NEJM199909163411201 · DOI · Paper page
  130. Packer, 1987, Calcium-channel blockade in the management of severe chronic congestive heart failure: a bridge too far, Circulation, 75, V56
  131. Packer, 1986, Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure, Am J Med, 80, 23, 10.1016/0002-9343(86)90337-2 · DOI
  132. Packer, 1987, Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure, Am J Kidney Dis, 10, 66
  133. Reid, 1986, Epinephrine-induced hypokalemia: the role of beta adrenoceptors, Am J Cardiol, 57, 23F, 10.1016/0002-9149(86)90884-2 · DOI
  134. Packer, 1990, Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure, Am J Cardiol, 65, 45E, 10.1016/0002-9149(90)90251-U · DOI
  135. Schwartz, 1978, Potassium-related cardiac arrhythmias and their treatment, Angiology, 29, 194, 10.1177/000331977802900302 · DOI
  136. Rude, 1989, Physiology of magnesium metabolism and the important role of magnesium in potassium deficiency, Am J Cardiol, 63, 31G, 10.1016/0002-9149(89)90216-6 · DOI
  137. Rich, 1995, A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure, N Engl J Med, 333, 1190, 10.1056/NEJM199511023331806 · DOI · Paper page
  138. Shah, 1998, Prevention of hospitalizations for heart failure with an interactive home monitoring program, Am Heart J, 135, 373, 10.1016/S0002-8703(98)70310-2 · DOI · Paper page
  139. Fonarow, 1997, Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure, J Am Coll Cardiol, 30, 725, 10.1016/S0735-1097(97)00208-8 · DOI · Paper page
  140. Philbin, 1999, Comprehensive multidisciplinary programs for the management of patients with congestive heart failure, J Gen Intern Med, 14, 130, 10.1046/j.1525-1497.1999.00291.x · DOI
  141. Pitt, 2001, The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction, Cardiovasc Drugs Ther, 15, 79, 10.1023/A:1011119003788 · DOI · Paper page
  142. Uretsky, 2000, Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial, Circulation, 102, 611, 10.1161/01.CIR.102.6.611 · DOI · Paper page
  143. Luu, 1989, Diverse mechanisms of unexpected cardiac arrest in advanced heart failure, Circulation, 80, 1675, 10.1161/01.CIR.80.6.1675 · DOI · Paper page
  144. 1981, Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction, N Engl J Med, 304, 801, 10.1056/NEJM198104023041401 · DOI · Paper page
  145. 1982, A randomized trial of propranolol in patients with acute myocardial infarction, JAMA, 247, 1707, 10.1001/jama.1982.03320370021023 · DOI · Paper page
  146. Packer, 1985, Sudden unexpected death in patients with congestive heart failure: a second frontier, Circulation, 72, 681, 10.1161/01.CIR.72.4.681 · DOI · Paper page
  147. Kjekshus, 1990, Arrhythmias and mortality in congestive heart failure, Am J Cardiol, 65, 42I, 10.1016/0002-9149(90)90125-K · DOI · Paper page
  148. Packer, 1992, Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure, Circulation, 85, I50
  149. Twidale, 1998, Comparison of the effects of AV nodal ablation versus AV nodal modification in patients with congestive heart failure and uncontrolled atrial fibrillation, Pacing Clin Electrophysiol, 21, 641, 10.1111/j.1540-8159.1998.tb00119.x · DOI
  150. Coplen, 1990, Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion, Circulation, 82, 1106, 10.1161/01.CIR.82.4.1106 · DOI · Paper page
  151. Waldo, 1996, Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction, Lancet, 348, 7, 10.1016/S0140-6736(96)02149-6 · DOI · Paper page
  152. Pratt, 1998, Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?, Am J Cardiol, 81, 869, 10.1016/S0002-9149(98)00006-X · DOI
  153. Du, 1995, Sympatholytic action of intravenous amiodarone in the rat heart, Circulation, 91, 462, 10.1161/01.CIR.91.2.462 · DOI
  154. Doval, 1994, Randomised trial of low-dose amiodarone in severe congestive heart failure, Lancet, 344, 493, 10.1016/S0140-6736(94)91895-3 · DOI · Paper page
  155. Singh, 1995, Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia, N Engl J Med, 333, 77, 10.1056/NEJM199507133330201 · DOI · Paper page
  156. Massie, 1996, Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure, Circulation, 93, 2128, 10.1161/01.CIR.93.12.2128 · DOI · Paper page
  157. Kadish, 2004, Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy, N Engl J Med, 350, 2151, 10.1056/NEJMoa033088 · DOI · Paper page
  158. Soejima, 2001, Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction: short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping, Circulation, 104, 664, 10.1161/hc3101.093764 · DOI · Paper page
  159. Silverman, 1995, Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy, Am J Cardiol, 75, 460, 10.1016/S0002-9149(99)80581-5 · DOI
  160. Fried, 1999, Electrical and hemodynamic correlates of the maximal rate of pressure increase in the human left ventricle, J Card Fail, 5, 8, 10.1016/S1071-9164(99)90019-2 · DOI
  161. Wilensky, 1988, Serial electrocardiographic changes in idiopathic dilated cardiomyopathy confirmed at necropsy, Am J Cardiol, 62, 276, 10.1016/0002-9149(88)90225-1 · DOI · Paper page
  162. Grines, 1989, Functional abnormalities in isolated left bundle branch block, Circulation, 79, 845, 10.1161/01.CIR.79.4.845 · DOI · Paper page
  163. Xiao, 1991, Effect of left bundle branch block on diastolic function in dilated cardiomyopathy, Br Heart J, 66, 443, 10.1136/hrt.66.6.443 · DOI · Paper page
  164. Takeshita, 1974, Effect of intermittent left bundle branch block on left ventricular performance, Am J Med, 56, 251, 10.1016/0002-9343(74)90604-4 · DOI
  165. Anderson, 1991, Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States, Am Heart J, 121, 1956, 10.1016/0002-8703(91)90832-3 · DOI
  166. Hatzizacharias, 1999, Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure, Am Heart J, 138, 241, 10.1016/S0002-8703(99)70107-9 · DOI
  167. Cadel, 1986, Effects of digoxin, placebo and ibopamine on exercise tolerance and cardiac rhythm of patients with chronic post-infarct left ventricular failure, Arzneimittelforschung, 36, 376
  168. Colucci, 1993, Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure, J Am Coll Cardiol, 22, 113A, 10.1016/0735-1097(93)90473-E · DOI
  169. DiBianco, 1984, Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study, J Am Coll Cardiol, 4, 855, 10.1016/S0735-1097(84)80044-3 · DOI
  170. Glover, 1985, Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade?, Br Heart J, 53, 208, 10.1136/hrt.53.2.208 · DOI
  171. Goldberg, 1991, Effectiveness of imazodan for treatment of chronic congestive heart failure, Am J Cardiol, 68, 631, 10.1016/0002-9149(91)90356-P · DOI
  172. Massie, 1985, Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial, Circulation, 71, 963, 10.1161/01.CIR.71.5.963 · DOI · Paper page
  173. Narahara, 1991, Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial, Am Heart J, 121, 1471, 10.1016/0002-8703(91)90154-A · DOI
  174. Roubin, 1984, Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol, Circulation, 69, 955, 10.1161/01.CIR.69.5.955 · DOI
  175. Uretsky, 1990, Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure, Circulation, 82, 774, 10.1161/01.CIR.82.3.774 · DOI · Paper page
  176. van Veldhuisen, 1993, Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT), J Am Coll Cardiol, 22, 1564, 10.1016/0735-1097(93)90579-P · DOI · Paper page
  177. Weber, 1982, Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure, Circulation, 66, 1262, 10.1161/01.CIR.66.6.1262 · DOI
  178. Cohn, 1998, A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure, N Engl J Med, 339, 1810, 10.1056/NEJM199812173392503 · DOI · Paper page
  179. Cowley, 1994, Treatment of severe heart failure: quantity or quality of life?, Br Heart J, 72, 226, 10.1136/hrt.72.3.226 · DOI
  180. Feldman, 1993, Effects of vesnarinone on morbidity and mortality in patients with heart failure, N Engl J Med, 329, 149, 10.1056/NEJM199307153290301 · DOI · Paper page
  181. Hampton, 1997, Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure, Lancet, 349, 971, 10.1016/S0140-6736(96)10488-8 · DOI · Paper page
  182. Lubsen, 1996, Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial, Heart, 76, 223, 10.1136/hrt.76.3.223 · DOI · Paper page
  183. Packer, 1991, Effect of oral milrinone on mortality in severe chronic heart failure, N Engl J Med, 325, 1468, 10.1056/NEJM199111213252103 · DOI · Paper page
  184. Cesario, 1998, Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study, Am Heart J, 135, 121, 10.1016/S0002-8703(98)70352-7 · DOI
  185. Leier, 1998, Parenteral inotropic support for advanced congestive heart failure, Prog Cardiovasc Dis, 41, 207, 10.1016/S0033-0620(98)80056-X · DOI
  186. Marius-Nunez, 1996, Intermittent inotropic therapy in an outpatient setting: a cost- effective therapeutic modality in patients with refractory heart failure, Am Heart J, 132, 805, 10.1016/S0002-8703(96)90315-4 · DOI
  187. Applefeld, 1987, Outpatient dobutamine and dopamine infusions in the management of chronic heart failure: clinical experience in 21 patients, Am Heart J, 114, 589, 10.1016/0002-8703(87)90757-5 · DOI
  188. Elis, 1998, Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study, Clin Pharmacol Ther, 63, 682, 10.1016/S0009-9236(98)90092-3 · DOI
  189. Brater, 1980, Furosemide in patients with heart failure: shift in dose-response curves, Clin Pharmacol Ther, 28, 182, 10.1038/clpt.1980.148 · DOI
  190. Dormans, 1996, Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion, J Am Coll Cardiol, 28, 376, 10.1016/0735-1097(96)00161-1 · DOI · Paper page
  191. Cotter, 1997, Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure, Clin Pharmacol Ther, 62, 187, 10.1016/S0009-9236(97)90067-9 · DOI
  192. Faris, 2006, Diuretics for heart failure, Cochrane Database Syst Rev, 10.1002/14651858.CD003838.pub2 · DOI
  193. Costanzo, 2005, Early ultrafiltration in patients with decompensated heart failure and diuretic resistance, J Am Coll Cardiol, 46, 2047, 10.1016/j.jacc.2005.05.099 · DOI · Paper page
  194. Domanski, 2003, Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD), J Am Coll Cardiol, 42, 705, 10.1016/S0735-1097(03)00765-4 · DOI · Paper page
  195. Cicoira, 2002, Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure, J Am Coll Cardiol, 40, 304, 10.1016/S0735-1097(02)01965-4 · DOI · Paper page
  196. Faris, 2002, Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials, Int J Cardiol, 82, 149, 10.1016/S0167-5273(01)00600-3 · DOI · Paper page
  197. Jessup, 2006, J Heart Lung Transplant, 25, 1003, 10.1016/j.healun.2006.06.007 · DOI
  198. McAlister, 2001, A systematic review of randomized trials of disease management programs in heart failure, Am J Med, 110, 378, 10.1016/S0002-9343(00)00743-9 · DOI · Paper page
  199. Whellan, 2005, Metaanalysis and review of heart failure disease management randomized controlled clinical trials, Am Heart J, 149, 722, 10.1016/j.ahj.2004.09.023 · DOI · Paper page
  200. Yancy, 2007, The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design, Am Heart J, 153, 478, 10.1016/j.ahj.2007.02.004 · DOI

200 of 311 shown

Cited by

See all 215

Metadata

Authors
Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., Stevenson, L. W., & Yancy, C. W.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2009-04
Volume
53
Issue
15
Pages
1343-1382
ISSN
0735-1097 (ISSN-L)
OpenAlex
W3023105181
Cited by
215
References
28
FWCI
18.59
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. https://app.cochat.ai/papers/10.1016/j.jacc.2008.11.009
The paper
Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., Silver, M. A., Stevenson, L. W., & Yancy, C. W. (2009). 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2008.11.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.